Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SRP54 (ImmuneEditome ID:6729)

1. Gene summary of enriched editing regions for SRP54

Gene summary

Gene information	Gene symbol	SRP54
	Gene ID	6729
	GeneSynonyms	SCN8
	GeneCytomap	14q13.2
	GeneType	protein-coding
	GeneDescription	signal recognition particle subunit SRP54\|signal recognition particle 54 kDa protein\|signal recognition particle 54kD\|signal recognition particle 54kDa
	GeneModificationdate	20230517
	UniprotID	P61011;A0A7I2V591;G3V4F7;A0A7I2V584;G3V346;A0A7I2V5S0;A0A7P0PJI2;A0A7I2V5K0;G3V3L9;G3V480
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr14:35001242-35002247:+	ENST00000555535.1	ENSG00000100883.10	SRP54	ncRNA_intronic	AluSp,AluJb,FLAM_C	chr14:35001242-35002247:+.alignment
chr14:35005081-35005655:+	ENST00000216774.9	ENSG00000100883.10	SRP54	intronic	AluJr,MER58A	chr14:35005081-35005655:+.alignment
chr14:35005081-35005655:+	ENST00000546080.4	ENSG00000100883.10	SRP54	intronic	AluJr,MER58A	chr14:35005081-35005655:+.alignment
chr14:35005081-35005655:+	ENST00000555557.4	ENSG00000100883.10	SRP54	intronic	AluJr,MER58A	chr14:35005081-35005655:+.alignment
chr14:35005081-35005655:+	ENST00000556380.2	ENSG00000100883.10	SRP54	intronic	AluJr,MER58A	chr14:35005081-35005655:+.alignment
chr14:35005081-35005655:+	ENST00000556994.4	ENSG00000100883.10	SRP54	intronic	AluJr,MER58A	chr14:35005081-35005655:+.alignment
chr14:35005081-35005655:+	ENST00000630962.1	ENSG00000100883.10	SRP54	intronic	AluJr,MER58A	chr14:35005081-35005655:+.alignment
chr14:35021371-35027725:+	ENST00000216774.9	ENSG00000100883.10	SRP54	exonic	(TTT)n,L1ME4a,AluJb,(TTGTTT)n,AluSc,(T)n,L3,(AC)n,AluSz,(TTTTAC)n,L2a,AluSx4,AluSg4,L1ME3Cz	chr14:35021371-35027725:+.alignment
chr14:35021371-35027725:+	ENST00000546080.4	ENSG00000100883.10	SRP54	exonic	(TTT)n,L1ME4a,AluJb,(TTGTTT)n,AluSc,(T)n,L3,(AC)n,AluSz,(TTTTAC)n,L2a,AluSx4,AluSg4,L1ME3Cz	chr14:35021371-35027725:+.alignment
chr14:35021371-35027725:+	ENST00000555557.4	ENSG00000100883.10	SRP54	exonic	(TTT)n,L1ME4a,AluJb,(TTGTTT)n,AluSc,(T)n,L3,(AC)n,AluSz,(TTTTAC)n,L2a,AluSx4,AluSg4,L1ME3Cz	chr14:35021371-35027725:+.alignment
chr14:35021371-35027725:+	ENST00000556994.4	ENSG00000100883.10	SRP54	exonic	(TTT)n,L1ME4a,AluJb,(TTGTTT)n,AluSc,(T)n,L3,(AC)n,AluSz,(TTTTAC)n,L2a,AluSx4,AluSg4,L1ME3Cz	chr14:35021371-35027725:+.alignment

Top

2. Tumor-specific enriched editing regions for SRP54

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr14:35021371-35027725:+	BRCA	EER	4.0967e-02
ENSG00000100883.10,SRP54	BRCA	EAG	4.9554e-02
chr14:35021371-35027725:+	THCA	EER	6.8808e-04
ENSG00000100883.10,SRP54	THCA	EAG	6.8808e-04

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr14:35001242-35002247:+	STAD	Path	EER	3.3316e-02	2.2919e-02	0.3386

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for SRP54

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr14:35021371-35027725:+

ESCA

EER

ENSG00000221184,MIR1254-1

-0.4525

3.0752e-04

2.3844e-07

-0.4346

T_cells_CD4_memory_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr14:35021371-35027725:+

ESCA

EER

ENSG00000221184,MIR1254-1

-0.4525

3.0752e-04

2.3844e-07

-0.4346

T_cells_CD4_memory_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr14:35021371-35027725:+

ESCA

EER

ENSG00000221184,MIR1254-1

-0.4525

3.0752e-04

2.3844e-07

-0.4346

T_cells_CD4_memory_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr14:35021371-35027725:+

ESCA

EER

ENSG00000221184,MIR1254-1

-0.4525

3.0752e-04

2.3844e-07

-0.4346

T_cells_CD4_memory_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results

Top

4. Enriched editing regions and immune related splicing for SRP54

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000100883.10,SRP54

ESCA

EAG

ENSG00000113648.12

chr5

135343259:135343362:135345967:135346057

-0.1476

1.3671e-02

3.4850e-07

-0.4277

ACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

T_cells_follicular_helper

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

ENSG00000100883.10,SRP54

ESCA

EAG

ENSG00000161547.10

chr17

76734118:76735158:76735771:76735803

-0.3794

2.6706e-02

3.1609e-07

-0.4291

ACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_P53_PATHWAY

chr14:35021371-35027725:+

ESCA

EER

ENSG00000185189.11

chr8

143837622:143838938:143839016:143839100

-0.4216

5.3983e-03

2.3952e-06

-0.4016

IGF2BP2;TAF15

NRBP2

GSVA_HALLMARK_MYOGENESIS

chr14:35021371-35027725:+

ESCA

EER

ENSG00000113648.12

chr5

135343259:135343362:135345967:135346057

-0.1413

2.1022e-02

1.3143e-06

-0.4095

IGF2BP2;TAF15

T_cells_follicular_helper

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

chr14:35021371-35027725:+

ESCA

EER

ENSG00000104613.7

chr8

19845662:19845797:19849161:19849239

-0.3965

2.6235e-03

2.6044e-06

-0.4256

IGF2BP2;TAF15

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V1

chr14:35021371-35027725:+

ESCA

EER

ENSG00000161547.10

chr17

76734118:76735158:76735771:76735803

-0.3798

2.3256e-02

3.8280e-07

-0.4278

IGF2BP2;TAF15

T_cells_CD4_memory_resting

GSVA_HALLMARK_P53_PATHWAY

More results

Top

5. Enriched editing regions and immune infiltration for SRP54

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr14:35021371-35027725:+	BLCA	EER	T_cells_CD4_memory_activated	2.6236e-02	0.2201
ENSG00000100883.10,SRP54	BLCA	EAG	T_cells_CD4_memory_activated	2.5913e-02	0.2206
chr14:35021371-35027725:+	BRCA	EER	NK_cells_activated	9.6813e-03	0.1157
ENSG00000100883.10,SRP54	BRCA	EAG	NK_cells_activated	4.3061e-03	0.1275
chr14:35021371-35027725:+	CESC	EER	Macrophages_M0	1.9078e-02	-0.2377
ENSG00000100883.10,SRP54	CESC	EAG	Macrophages_M0	1.9067e-02	-0.2377
chr14:35021371-35027725:+	COAD	EER	Dendritic_cells_activated	8.1031e-03	0.2822
ENSG00000100883.10,SRP54	COAD	EAG	Dendritic_cells_activated	1.2725e-02	0.2661
chr14:35021371-35027725:+	ESCA	EER	T_cells_CD8	6.8797e-03	0.2360
ENSG00000100883.10,SRP54	ESCA	EAG	T_cells_CD8	2.7782e-03	0.2594
chr14:35021371-35027725:+	GBM	EER	Mast_cells_activated	9.2203e-03	0.2968
ENSG00000100883.10,SRP54	GBM	EAG	Eosinophils	2.3397e-02	0.2582
ENSG00000100883.10,SRP54	HNSC	EAG	Dendritic_cells_activated	6.5551e-03	0.4179
chr14:35021371-35027725:+	KIRC	EER	T_cells_gamma_delta	1.5681e-03	0.2560
ENSG00000100883.10,SRP54	KIRC	EAG	T_cells_gamma_delta	3.8660e-03	0.2345
chr14:35021371-35027725:+	KIRP	EER	T_cells_CD4_memory_activated	7.5489e-06	0.4620
ENSG00000100883.10,SRP54	KIRP	EAG	T_cells_CD4_memory_activated	7.5489e-06	0.4620
chr14:35021371-35027725:+	LAML	EER	Eosinophils	3.4285e-02	0.1772
ENSG00000100883.10,SRP54	LAML	EAG	T_cells_CD4_memory_activated	1.0036e-02	-0.2110
chr14:35021371-35027725:+	LGG	EER	Neutrophils	1.6057e-03	0.2195
ENSG00000100883.10,SRP54	LGG	EAG	Neutrophils	1.6057e-03	0.2195
chr14:35021371-35027725:+	LUSC	EER	Macrophages_M2	1.4054e-02	0.1533
ENSG00000100883.10,SRP54	LUSC	EAG	Macrophages_M2	1.4054e-02	0.1533
chr14:35021371-35027725:+	OV	EER	Macrophages_M1	8.2166e-04	0.2565
ENSG00000100883.10,SRP54	OV	EAG	Macrophages_M1	7.9881e-04	0.2563
chr14:35021371-35027725:+	PAAD	EER	B_cells_naive	2.4373e-02	-0.2385
ENSG00000100883.10,SRP54	PAAD	EAG	B_cells_naive	2.4373e-02	-0.2385
chr14:35021371-35027725:+	PCPG	EER	Macrophages_M0	4.9216e-02	0.2949
ENSG00000100883.10,SRP54	PCPG	EAG	Macrophages_M0	4.9216e-02	0.2949
chr14:35021371-35027725:+	PRAD	EER	Mast_cells_resting	3.3444e-02	0.1805
ENSG00000100883.10,SRP54	PRAD	EAG	Mast_cells_resting	4.1013e-02	0.1736
chr14:35021371-35027725:+	SARC	EER	T_cells_CD4_memory_activated	1.1295e-03	0.4204
ENSG00000100883.10,SRP54	SARC	EAG	T_cells_CD4_memory_activated	1.1295e-03	0.4204
chr14:35021371-35027725:+	SKCM	EER	NK_cells_activated	2.6552e-03	0.2931
ENSG00000100883.10,SRP54	SKCM	EAG	NK_cells_activated	2.6552e-03	0.2931
chr14:35001242-35002247:+	STAD	EER	Plasma_cells	2.7185e-02	0.3222
chr14:35021371-35027725:+	STAD	EER	Dendritic_cells_activated	4.2244e-03	0.1888
ENSG00000100883.10,SRP54	STAD	EAG	Dendritic_cells_activated	2.8949e-02	0.1444
chr14:35021371-35027725:+	THYM	EER	B_cells_memory	1.3019e-02	0.4045
ENSG00000100883.10,SRP54	THYM	EAG	B_cells_memory	1.3019e-02	0.4045

Top

6. Enriched editing regions and immune gene sets for SRP54

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr14:35021371-35027725:+	BRCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	6.7899e-05	0.1774
ENSG00000100883.10,SRP54	BRCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	5.3052e-05	0.1797
chr14:35021371-35027725:+	CESC	GSVA_HALLMARK_APOPTOSIS	EER	5.1790e-03	0.2817
ENSG00000100883.10,SRP54	CESC	GSVA_HALLMARK_APOPTOSIS	EAG	5.2511e-03	0.2813
ENSG00000100883.10,SRP54	ESCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	3.7176e-03	0.2518
chr14:35021371-35027725:+	ESCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	4.0423e-03	0.2505
ENSG00000100883.10,SRP54	GBM	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	6.2641e-03	0.3089
chr14:35021371-35027725:+	GBM	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	9.2520e-03	0.2967
ENSG00000100883.10,SRP54	HNSC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	4.9758e-03	0.4304
ENSG00000100883.10,SRP54	KIRC	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	8.8120e-04	0.2688
chr14:35021371-35027725:+	KIRC	GSVA_HALLMARK_MTORC1_SIGNALING	EER	9.3040e-04	0.2676
ENSG00000100883.10,SRP54	LAML	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	6.8764e-03	-0.2213
chr14:35005081-35005655:+	LAML	GSVA_HALLMARK_HEME_METABOLISM	EER	1.4759e-02	-0.2535
chr14:35021371-35027725:+	LAML	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.1537e-02	0.2107
ENSG00000100883.10,SRP54	LGG	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	4.3436e-03	0.1989
chr14:35021371-35027725:+	LGG	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	4.3436e-03	0.1989
ENSG00000100883.10,SRP54	LIHC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	4.2410e-02	-0.3266
chr14:35021371-35027725:+	LUAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	8.7648e-04	0.1872
ENSG00000100883.10,SRP54	LUAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	8.7701e-04	0.1872
ENSG00000100883.10,SRP54	OV	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	1.6105e-02	0.1854
chr14:35021371-35027725:+	OV	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.7755e-02	0.1833
ENSG00000100883.10,SRP54	PAAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.2308e-02	-0.2643
chr14:35021371-35027725:+	PAAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.2308e-02	-0.2643
ENSG00000100883.10,SRP54	PCPG	GSVA_HALLMARK_P53_PATHWAY	EAG	1.3138e-02	-0.3670
chr14:35021371-35027725:+	PCPG	GSVA_HALLMARK_P53_PATHWAY	EER	1.3138e-02	-0.3670
chr14:35021371-35027725:+	SARC	GSVA_HALLMARK_DNA_REPAIR	EER	3.1953e-02	0.2845
ENSG00000100883.10,SRP54	SARC	GSVA_HALLMARK_DNA_REPAIR	EAG	3.1953e-02	0.2845
ENSG00000100883.10,SRP54	STAD	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	1.0727e-02	0.1683
chr14:35021371-35027725:+	STAD	GSVA_HALLMARK_MYC_TARGETS_V1	EER	7.6799e-03	0.1761
chr14:35001242-35002247:+	STAD	GSVA_HALLMARK_COAGULATION	EER	7.3784e-03	0.3859
ENSG00000100883.10,SRP54	THCA	GSVA_HALLMARK_GLYCOLYSIS	EAG	5.0149e-03	0.1898
chr14:35021371-35027725:+	THCA	GSVA_HALLMARK_GLYCOLYSIS	EER	5.0149e-03	0.1898
ENSG00000100883.10,SRP54	THYM	GSVA_HALLMARK_HYPOXIA	EAG	7.5289e-03	0.4324
chr14:35021371-35027725:+	THYM	GSVA_HALLMARK_HYPOXIA	EER	7.5289e-03	0.4324

Top

7. Enriched editing regions and drugs for SRP54

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr14:35021371-35027725:+	BLCA	AS601245	EER	2.1871e-02	0.2268
ENSG00000100883.10,SRP54	BLCA	AS601245	EAG	2.0787e-02	0.2287
chr14:35021371-35027725:+	BRCA	GNF.2	EER	4.3558e-05	-0.1819
ENSG00000100883.10,SRP54	BRCA	GNF.2	EAG	3.0082e-05	-0.1855
chr14:35021371-35027725:+	CESC	CEP.701	EER	1.4992e-02	-0.2464
ENSG00000100883.10,SRP54	CESC	CEP.701	EAG	1.5112e-02	-0.2461
ENSG00000100883.10,SRP54	COAD	BI.2536	EAG	2.3857e-02	0.2421
chr14:35021371-35027725:+	COAD	GSK.650394	EER	4.6025e-02	0.2145
chr14:35021371-35027725:+	ESCA	Bleomycin	EER	1.1479e-07	-0.4448
chr14:35005081-35005655:+	ESCA	AZD8055	EER	2.5064e-02	0.4659
ENSG00000100883.10,SRP54	ESCA	Bleomycin	EAG	4.7806e-09	-0.4838
ENSG00000100883.10,SRP54	GBM	Erlotinib	EAG	6.9042e-05	-0.4376
chr14:35021371-35027725:+	GBM	Erlotinib	EER	1.1897e-04	-0.4272
ENSG00000100883.10,SRP54	HNSC	Cyclopamine	EAG	5.2799e-04	0.5177
chr14:35021371-35027725:+	KIRC	CHIR.99021	EER	8.3386e-03	0.2147
ENSG00000100883.10,SRP54	KIRC	CHIR.99021	EAG	6.6232e-03	0.2208
chr14:35021371-35027725:+	KIRP	Bexarotene	EER	2.4086e-04	0.3861
ENSG00000100883.10,SRP54	KIRP	Bexarotene	EAG	2.4086e-04	0.3861
ENSG00000100883.10,SRP54	LAML	JNK.Inhibitor.VIII	EAG	1.0396e-04	0.3136
chr14:35021371-35027725:+	LAML	AZD6482	EER	6.3957e-06	0.3673
chr14:35005081-35005655:+	LAML	AUY922	EER	2.5312e-04	0.3727
chr14:35021371-35027725:+	LGG	FTI.277	EER	4.5637e-03	0.1978
ENSG00000100883.10,SRP54	LGG	FTI.277	EAG	4.5637e-03	0.1978
ENSG00000100883.10,SRP54	LIHC	GW.441756	EAG	7.4284e-04	-0.5174
ENSG00000100883.10,SRP54	LUAD	AZD.0530	EAG	5.2125e-04	-0.1950
chr14:35021371-35027725:+	LUAD	AZD.0530	EER	5.3890e-04	-0.1945
ENSG00000100883.10,SRP54	LUSC	AP.24534	EAG	1.3093e-02	0.1549
chr14:35021371-35027725:+	LUSC	AP.24534	EER	1.3093e-02	0.1549
ENSG00000100883.10,SRP54	OV	KU.55933	EAG	3.4580e-04	-0.2736
chr14:35021371-35027725:+	OV	KU.55933	EER	6.3316e-05	-0.3053
chr14:35021371-35027725:+	PAAD	AP.24534	EER	1.8545e-02	0.2492
ENSG00000100883.10,SRP54	PAAD	AP.24534	EAG	1.8545e-02	0.2492
ENSG00000100883.10,SRP54	PCPG	ABT.263	EAG	2.1567e-03	-0.4456
chr14:35021371-35027725:+	PCPG	ABT.263	EER	2.1567e-03	-0.4456
ENSG00000100883.10,SRP54	SARC	CCT007093	EAG	1.9913e-03	0.4010
chr14:35021371-35027725:+	SARC	CCT007093	EER	1.9913e-03	0.4010
ENSG00000100883.10,SRP54	SKCM	Bosutinib	EAG	1.9429e-03	-0.3033
chr14:35021371-35027725:+	SKCM	Bosutinib	EER	1.9429e-03	-0.3033
ENSG00000100883.10,SRP54	STAD	DMOG	EAG	7.1200e-03	0.1774
chr14:35021371-35027725:+	STAD	AZD6482	EER	1.0080e-03	0.2164
chr14:35001242-35002247:+	STAD	BI.2536	EER	2.4500e-02	0.3278
ENSG00000100883.10,SRP54	THCA	CCT007093	EAG	1.3254e-04	0.2566
chr14:35021371-35027725:+	THCA	CCT007093	EER	1.3254e-04	0.2566
chr14:35021371-35027725:+	THYM	Doxorubicin	EER	1.1383e-04	0.5919
ENSG00000100883.10,SRP54	THYM	Doxorubicin	EAG	1.1383e-04	0.5919
ENSG00000100883.10,SRP54	UCEC	CHIR.99021	EAG	1.1381e-02	0.4229
chr14:35021371-35027725:+	UCEC	JNK.9L	EER	5.2430e-03	0.4681

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType